

# RAPID ALERT

DRAP ALERT No: I/S/02-25-

## PRESENCE OF COUNTERFEIT AND TRADEMARK INFRINGEMENT CASE OF LAROSCORBINE PLATINUM INJECTION IN THE MARKET

**Date:** 04<sup>th</sup> February, 2025

### Target Audience:

- Regulatory Field Force of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Pharmacies and medical stores

### Problem Statement:

M/s Roche Pakistan Limited, Karachi, has notified DRAP, regarding the sale of counterfeit '*Laroscobine Platinum Injection*' in the market across Pakistan. According to the principal, Roche manufactured and marketed Laroscobine until 2005. In that year, Roche sold the product and brand to Bayer AG. Therefore, any Laroscobine offered for sale, and which is labeled with the Roche logo or which claims that it was manufactured or marketed by Roche, is not a genuine Roche product. Further informed that as the product does not belong to Roche portfolio, tracing of the lot is not possible.

### Risk Statement:

The use of Laroscobine Platinum Injection is believed to brighten the skin and maintain skin elasticity. However, the administration of counterfeit products could result in treatment failure, worsening of the disease, or life threatening consequences.

### Identification of Counterfeit product





### **Action Initiated: -**

The Regulatory field force has been directed to conduct surveillance activities throughout the supply chain to confiscate the counterfeit product. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the supplier of such product should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of this product from the circulation.

### **Advice for Healthcare Professionals: -**

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using [Adverse Event Reporting Form](#) or online through this [link](#). Further information on reporting problems to DRAP is available on this [link](#).

### **Advice for Consumers:**

Consumers should not use this product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned product and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.



**Drug Regulatory Authority of Pakistan**

محفوظ، موثر اور معیاری اشیائے علاج